Reporter Cell Lines

Antibody drugs have undergone decades of research and development after the world’s first monoclonal antibody drug, muromonab-CD3. Antibody therapies have become the fastest growing biological drug field and have revolutionized the treatment landscape for wide array of diseases, especially in cancer. Presently, over 100 antibody drugs have been commercialized across the globe, playing an important role in clinical treatment in vitro diagnostics, research, and many other fields.

Cellular-level evaluation is a key indicator for drug efficacy in vitro and is widely used throughout the drug development process. However, when using conventional cells, many traditional analytical methods have disadvantages including low sensitivity, poor reproducibility, complicated operations, and low throughput. This is further exacerbated by the batch-to-batch variation in primary cells, and results in a significant bottleneck during antibody drug development.

Instead of using traditional cells, our reporter cell lines are constructed using genetic engineering to help standardize and minimize the batch-to-batch variation during cell passaging. Reporter cell lines are based on the drug mechanism of action (MOA) and helps various studies, including:

To meet the needs of new drug development, ACROBiosystems uses a luciferase reporter gene system to establish a reporter gene cell platform and continues to develop a series of high-quality reporter gene cell line products. The series of cell line products are verified for functionality and stability and designed to be applied to signal transduction function research, early drug discovery and screening, and CMC quality control release!